Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical... see more

CSE:BIOV - Post Discussion

BioVaxys Technology Corp. > Lipid Delivery Licences Can Be Valuable!
View:
Post by javaman12 on Nov 11, 2024 11:11pm

Lipid Delivery Licences Can Be Valuable!

Just a reminder! Big pharmaceutical companies pay big dollars to biotech companies for good lipid delivery platforms. 

BioVaxys may have the best of these available to market. It may be just a matter of providing some better education and getting this information out to the public, the investment community and big pharma to let them know what the DPX delivery lipid delivery is all about and where they can get it! 

Management knows that they have some significant work to do in this regard. But they are working hard to get the best message out! And now, the pharmaceutical industry has finally begun to listen!

BioVaxys President and Chief Operating Officer Kenneth Kovan says “We are pleased to join the RRPV consortium with organizations including Astra-Zeneca, Battelle, Deutsches Zentrum fr Infektionsforschung e.V. (The German Center for Infection Research),Genentech, Ginkgo Bioworks, Inc., Novavax and Leidos. We believe DPX can play a major role in the development of BARDA’s priority vaccine programs, and having the ability to collaborate with such world-renowned consortium members will no doubt be a significant benefit for the Company.”

https://www.biovaxys.com/newsroom/biovaxys-to-participate-in-the-us-government-biomedical-advanced-research-and-development-authority-barda-rapid-response-partnership-vehicle-rrpv-vaccine-development-consortium

And maybe the new Trump administration may make the rules for multiple phase drug trials a little less expensive and easier to accomplish! Certainly, any newly appointed drug czar appointed by Donald Trump may try to make the rules for some of these big drug trials necessary to get FDA approval a little less onerous and much less expensive to finish. 

I realize that since Trump was elected President that many in the investment community have been selling a lot their junior investment strategies and are presently chasing a virtual coin base investment like bitcoin, etherium or doge coin. A lot of big money is being made!

But eventually this part of the market will come back to reality when that market plunges back down. It always happens!

It is presently trading upwards on sentiment or wishful thinking! But why fight the trend while it remains your friend? But when that trend reverses quickly, a lot of money, can still be lost!

Why not return later to one of the best biotech opportunites out there?

Make another good investment decision! 

Make your extra money and then reconsider investing in BioVaxys. We will wait! Not sure about the share price though!

                                             Good investing to all!

                                                All the best, Java


      The following is a repeat of a lengthy BioVaxys presentation. But it's well worth a listen!


                         




 
Comment by Hideaway on Nov 12, 2024 2:29pm
Javaman,I agree with you.DPX has tremendous potential and management is doing great PR work promoting the benefits.No comparison to the lacklustre effort of IMV. Merck financed the start of the clinical trials for ovarian cancer and experienced first hand the benefits of DPX technology.Unfortunately the trials only had a handful of patients and even with encouraging results,Merck walked away and ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities